After gaining extensive ground in managing obesity and metabolic disorders, it was only a matter of time for GLP-1 therapies to be tried for pet animals’ obesities. Last week at ACVIM 2026 in Seattle, data was presented on a novel GLP-1 fusion protein therapy managing feline obesity.
A novel long-acting GLP-1 fusion protein therapy has demonstrated encouraging preclinical results for the management of obesity in cats, raising hopes for a new class of veterinary metabolic medicines that could transform the treatment of one of the fastest-growing health challenges in companion animals.
Data presented at the ACVIM Forum 2026 in Seattle showed that the investigational therapy, AKS-562c, safely reduced food intake and limited weight gain in healthy cats over a 12-week evaluation period, with researchers reporting no treatment-related toxicities.
The findings position the once-weekly injectable therapy as a potential future option for veterinarians seeking effective long-term management of feline obesity and its associated metabolic disorders.
Growing Global Health Challenge
Obesity has become one of the most prevalent nutritional disorders affecting companion animals worldwide. Veterinary studies estimate that 35–60% of owned cats in developed countries are overweight or obese, with prevalence continuing to rise as indoor lifestyles, reduced physical activity and excessive caloric intake become increasingly common.
Excess body weight substantially increases the risk of numerous chronic diseases, including:
-
Feline diabetes mellitus
-
Osteoarthritis
-
Reduced mobility
-
Hepatic lipidosis
-
Cardiovascular stress
-
Lower quality of life
-
Shortened lifespan
Veterinary experts increasingly recognize obesity as a chronic disease rather than simply a nutritional issue, emphasizing the need for medical interventions alongside dietary management and lifestyle modification.
Promising Results from a Once-Weekly Therapy
The investigational molecule AKS-562c is a long-acting glucagon-like peptide-1 (GLP-1) fusion protein, designed to enhance satiety and regulate appetite through mechanisms similar to those used in human metabolic medicine.
During the 12-week preclinical evaluation presented at the ACVIM Forum, researchers reported that treated cats experienced:
-
Significant reductions in voluntary food intake
-
Controlled body weight gain compared with untreated animals
-
Good overall tolerability
-
No treatment-related adverse events or toxicological concerns
-
Sustained activity following once-weekly administration
The study suggests that prolonged GLP-1 receptor activation may provide a practical therapeutic strategy for managing chronic obesity in companion animals while reducing the burden of daily medication administration.
Veterinary Medicine Follows Human Metabolic Innovation
The research reflects growing interest in adapting GLP-1 biology for veterinary medicine following the remarkable success of GLP-1 receptor agonists in human healthcare.
Medicines such as Semaglutide and Tirzepatide have transformed obesity and diabetes treatment in people by reducing appetite, promoting weight loss and improving metabolic control.
Veterinary researchers are now exploring whether similar physiological pathways can safely address obesity in companion animals, where therapeutic options remain limited.
Unlike humans, however, feline metabolism presents unique physiological characteristics, requiring species-specific formulations and careful evaluation of safety, efficacy and long-term metabolic effects.
Potential Impact Beyond Weight Management
Researchers emphasized that effective control of body weight could deliver benefits extending well beyond cosmetic improvements.
Obesity is a major risk factor for secondary conditions including osteoarthritis, insulin resistance and diabetes, all of which contribute substantially to veterinary healthcare costs and reduced animal welfare.
By reducing caloric intake before severe obesity develops, therapies such as AKS-562c could potentially:
-
Lower the incidence of feline diabetes
-
Delay progression of degenerative joint disease
-
Improve mobility in ageing cats
-
Enhance quality of life
-
Support healthier ageing
-
Reduce long-term veterinary interventions
These broader health benefits are increasingly important as companion animals live longer and chronic diseases become more common.
Expanding Veterinary Metabolic Therapeutics
The presentation also highlights the emergence of metabolic medicine as a new frontier within companion animal therapeutics.
Historically, veterinary obesity management has relied primarily on calorie restriction, prescription diets and increased physical activity. While these approaches remain essential, long-term compliance can be difficult for both owners and patients.
Pharmaceutical therapies targeting appetite regulation may provide veterinarians with additional tools for cases where conventional management proves insufficient.
Industry analysts note that growing pet humanization, increasing expenditure on preventive healthcare and greater owner awareness of obesity-related diseases are creating attractive commercial opportunities for innovative metabolic therapies.
Market Opportunity
The companion animal obesity market is expected to expand steadily during the remainder of the decade, supported by increasing veterinary visits, improved diagnostic screening and greater recognition of obesity as a chronic medical condition.
The global companion animal therapeutics market is already valued at tens of billions of dollars annually, with metabolic disorders representing one of the fastest-evolving areas of research and development.
Should future clinical studies confirm safety and efficacy in client-owned cats, long-acting GLP-1 therapies could establish an entirely new therapeutic category within feline medicine.
Looking Ahead
Although AKS-562c remains an investigational therapy and will require additional clinical evaluation before regulatory approval, the results presented at the ACVIM Forum 2026 represent an important scientific milestone.
The study demonstrates that weekly GLP-1-based treatment can safely influence appetite regulation in cats without significant safety concerns over a 12-week observation period.
As veterinary medicine increasingly embraces precision therapeutics inspired by advances in human healthcare, metabolic interventions such as AKS-562c may become valuable additions to the clinical management of obesity, helping veterinarians reduce the burden of diabetes, osteoarthritis and other obesity-related diseases in the growing global cat population.
